Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Interferon: Hope or hindrance?
Washington - In a retrospective review of 135 patients diagnosed with a primary, thick melanoma (Breslow ? 4mm) and/or pathological evidence of regional nodal metastasis, further analysis shows significant differences between those who undergo adjuvant interferon alfa-2b (IFN_2b) therapy and those who decline, said Tracy L. Bialy, M.D., M.P.H.
Related Videos
Related Content
